hiPSC-derived macrophages have been engineered to express CD20-CAR with FcγR1 (Senju et al., 2011), CD19, or mesothelin CAR with CD3ζ signaling domains (Zhang et al., 2020), enabling them to destroy leukemic cells or ovarian cancers. This evidence concerns the gene CD19 and ovarian carcinoma.